We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Understanding Cancer Immunoediting Will Aid Vaccine Development

By LabMedica International staff writers
Posted on 29 Feb 2012
The body’s immune system employs the process of cancer immunoediting to eliminate tumor cells bearing highly antigenic mutant proteins and to suppress growth of those cancer cells that lack these antigens.

Cancer immunoediting, the process by which the immune system controls tumor outgrowth and shapes tumor immunogenicity, is comprised of three phases: elimination, equilibrium, and escape. More...
Although many immune components that participate in this process are known, its underlying mechanisms remain poorly defined. To understand better the molecular basis that drives immunoediting, investigators at Washington University School of Medicine (St. Louis, MO, USA) induced the formation of sarcomas in a line of immunocompromised mice.

The investigators then used massive parallel DNA sequencing to characterize mutations expressed on the sarcoma cells, which were phenotypically similar to unedited primary tumors growing in immunocompetent hosts.

Results published in the February 16, 2012, issue of the journal Nature revealed that the genome of the sarcoma cells contained 3,743 mutations. Using class I prediction algorithms, they identified the protein produced by the mutant spectrin-beta2 gene as a potential rejection antigen of the sarcoma and validated this prediction by conventional antigen expression cloning and detection. They also demonstrated that cancer immunoediting occurred via a T-cell-dependent immunoselection process that promoted outgrowth of preexisting tumor cell clones lacking highly antigenic mutant spectrin-beta2 and other potential strong antigens.

“The idea would be to make a vaccine that helps the immune system recognize and attack six or seven of these mutated proteins in a cancer,” said senior author Dr. Robert Schreiber, professor of pathology and immunology at Washington University School of Medicine. “Therapeutically, that could be very helpful.”

“Many of the cancer genome projects now under way are looking for the “driver” mutations, or the mutations that cause the cancers,” said Dr. Schreiber. “Our results suggest there may be additional information in the sequencing data that can help us make the immune system attack cancers. Until very recently, this work would have been impractical because of the costs involved, but the technology has improved and prices have come down, and now it is possible to obtain this genetic information for a few thousand dollars instead of a million.”

Related Links:

Washington University School of Medicine



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Parainfluenza Virus Test
PARAINFLUENZA ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.